Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions

Kristen Farrell, Michael H Antoni, Kristen Farrell, Michael H Antoni

Abstract

Objective: To summarize physiological and psychological characteristics that are common among women diagnosed with polycystic ovary syndrome (PCOS) and provide evidence suggesting that addressing psychological disturbances can reduce or alleviate physical symptoms of PCOS through behavioral pathways and physiological pathways.

Method(s): Empirical studies and expert consensuses pertaining to physiological, psychological, and medical management aspects of PCOS were identified and presented in this review. Articles were identified by searching Pubmed, PsycInfo, Medline ISI, CINAHL, or a Web browser (i.e., Google) using numerous combinations of terms pertaining to physiological, psychological, and medical management aspects of PCOS. An article was chosen to be included in this review if it reported findings and/or provided information that related to and helped support the main purpose(s) of this review article.

Result(s): Available literature on the physiological (i.e., hyperandrogenism, central obesity, inflammation, insulin resistance) and psychological (i.e., depression, anxiety, eating disorders) factors among women with PCOS provides evidence that these various aspects of PCOS are strongly interrelated.

Conclusion(s): The existence of these relationships among physiological and psychological factors strongly suggests that medical management of PCOS would greatly benefit from inclusion of psychological and behavioral approaches.

Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Figures

Figure
Figure
Proposed model of interrelationships among physiological and psychological characteristics in women with PCOS and how various pharmaceutical, psychological, and behavioral interventions might impact physiological and psychological abnormalities. In the Figure, the physiological and psychological characteristics common among PCOS women are represented by rectangles, and their direct relations are represented by arrows. Suggested interventions are enclosed in ovals, their dashed arrows indicating which physiological and/or psychological abnormalities they might directly impact.

References

    1. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovary syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781–785.
    1. Chang WY, Knochenbauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–1723.
    1. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12:324–332.
    1. Legro RS, Driscoll D, Strauss JF, 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14956–14960.
    1. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:53–58.
    1. Norman RJ, Dewailly D, Legro R, Hickey T. Polycystic ovary syndrome. Lancet. 2007;370:685–697.
    1. Franks S, McCarthy M, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278–285.
    1. Sharma ST, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab. 2006;20:245–260.
    1. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2002;77:255–258.
    1. Ehrmann DA, Barnes RB, Rosenfield RI, Cavaghan MK, Imperial J. Prevalance of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146.
    1. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod. 2001;16:1995–1998.
    1. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60:1–17.
    1. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metab Clin Exp. 1995;44:525–531.
    1. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–146.
    1. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–89.
    1. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001–2005.
    1. Cascella T, Palomba S, Di Sio I, Manguso F, Giallauria F, De Simone B, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008;1:153–159.
    1. Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA. Correlates of increased muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol. 2009;4:583–589.
    1. Georgopoulos NA, Saltamavros AD, Vervita V, Karkoulias K, Adonakis G, Decavalas G, et al. Basal metabolic rate is decreased in women with polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. Fertil Steril. 2009;92:250–255.
    1. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol. 1990;32:213–220.
    1. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet. 1988;1:870–872.
    1. Hirschberg AL, Naessen S, Stridesberg M, Brystrom B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol. 2004;19:79–87.
    1. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5-alpha reductase activity in polycystic ovary syndrome. Lancet. 1990;335:431–433.
    1. Chin D, Shackleton C, Prasad VK, Kohn B, David R, Imperato-McGinley J, et al. Increased 5 alpha-reductase and normal 11 beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13:253–259.
    1. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 betahydroxysteroid dehydrogenase. N Engl J Med. 1994;330:460–465.
    1. Lanzone A, Petraglia F, Fulghesu AM, Ciampelli M, Caruso A, Mancuso S. Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fertil Steril. 1995;63:1195–1199.
    1. Carmina E, Levin JH, Malizia G, Lobo RA. Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women. Fertil Steril. 1990;54:245–250.
    1. Battaglia C, Mancini F, Cianciosi A, Busacchi P, Persico N, Paradisi R, et al. Cardiovascular risk in normal weight, eumenorrheic, nonhirsute daughters of patients with polycystic ovary syndrome: a pilot study. Fertil Steril. 2008;92:240–249.
    1. Birdsall MA, Farquar CM, White HD. Association between polycystic ovaries and the extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 1997;126:32–35.
    1. Lakhani K, Seifalian AM, Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation. 2002;106:81–85.
    1. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2562–2568.
    1. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414–2421.
    1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843.
    1. Engin-Ustun Y, Ustun Y, Meydanli M, Kafkasli A, Yetkin G. Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome? Gynecol Endocrinol. 2006;22:324–328.
    1. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JI. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab. 2004;89:806–811.
    1. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009;91:207–212.
    1. Benson S, Hahn S, Tan S, Mann K, Janssen OE, Schedlowski M, et al. Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany. Hum Reprod. 2009;24:1446–1451.
    1. Tan S, Hahn S, Benson S, Janssen OE, Dietz T, Kimmig R, et al. Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod. 2008;23:2064–2071.
    1. Adali E, Yildizhan R, Kurdoglu M, Kolusari A, Edirne T, Sahin HG, et al. The relationship between clinic-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res. 2008;36:1188–1196.
    1. Mansson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landen M. Women with polycystic ovary syndrome are often depressed or anxious—a case control study. Psychoneuroendocrinology. 2008;33:1132–1138.
    1. Hollinrake E, Abreu A, Maifeld M, Van Voorhis B, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007;87:1369–1376.
    1. Stunkard AJ, Faith MS, Allison KC. Depression and obesity. Biol Psychiatry. 2003;54:330–337.
    1. Bishop SC, Basch S, Futterweit W. Polycystic ovary syndrome, depression, and affective disorders. Endocr Pract. 2009;15:475–482.
    1. Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol. 2003;16:33–37.
    1. Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, et al. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod. 2006;21:1092–1099.
    1. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J. 1993;69:186–189.
    1. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140:672–676.
    1. Keegan A, Liao LM, Boyle M. `Hirsutim': A psychological analysis. J Health Psychol. 2003;8:327–345.
    1. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:5801–5807.
    1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.
    1. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199–226.
    1. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993;49:11–27.
    1. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry. 1999;4:182–188.
    1. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401–412.
    1. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–684.
    1. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin N Am. 2009;29:309–320.
    1. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz, Roman A, Papp M, et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol. 1996;48:503–506.
    1. Dantzer R. Cytokine-induced sickness behavior: Where do we stand? Brain Behav Immun. 2001;15:7–24.
    1. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol. 1992;13:24–28.
    1. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, et al. Cytokines, “depression due to a general medical condition,” and antidepressant drugs. Adv Exp Med Biol. 1999;461:283–316.
    1. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol. 1997;72:155–161.
    1. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29:891–909.
    1. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and and cortico-releasing hormone. Proc Natl Acad Sci USA. 2000;97:325–330.
    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker Medical progress: Multiple sclerosis. N Engl J Med. 2000;343:938–952.
    1. Link H. The cytokine storm in multiple sclerosis. Mult Scler. 1998;4:12–15.
    1. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76:469–475.
    1. Pollak Y, Ovadia H, Goshen I, Gurevich R, Monsa K, Avitsur R, et al. Behavioral aspects of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000;104:31–36.
    1. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: Role of insulin resistance. J Clin Endocrinol Metab. 2001;86:517–520.
    1. Forbes EE, Bertocci MA, Gregory AM, Ryan ND, Axelson DA, Birmaher B, et al. Objective sleep in pediatric anxiety disorders and major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008;47:148–155.
    1. Vgontzas AN. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch Physiol Biochem. 2008;114:211–223.
    1. Mehra R, Redline S. Sleep apnea: a proinflammatory disorder that coaggregates with obesity. J Allergy Clin Immunol. 2008;121:1096–1102.
    1. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49:391–404.
    1. Nissel H, Hjemdahl P, Linde B, Beskow C, Lunell NO. Sympathoadrenal and cardiovascular responses to mental stress in pregnancy-induced hypertension. Obstet Gynecol. 1986;68:531–536.
    1. Gallinelli A, Matteo ML, Volpe A, Facchinetti F. Autonomic and neuroendocrine responses to stress in patients with functional hypothalamic secondary amenorrhea. Fertil Steril. 2000;73:812–816.
    1. Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, et al. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology. 2009;34:727–35.
    1. Drapeau V, Therrien F, Richard D, Tremblay A. Is visceral obesity a physiological adaptation to stress? Panminerva Med. 2003;45:189–195.
    1. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–850.
    1. Epel ES, McEwen B, Seeman T, Matthews K, Castellazzo G, Brownell KD, et al. Stress and body shape: Stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med. 2000;62:623–632.
    1. van Honk J, Tuiten A, Hermans E, Putman P, Koppeschaar H, Thijssen J, et al. A single administration of testosterone induces cardiac accelerative responses to angry faces in healthy young women. Beh Neuro. 2001;115:238–242.
    1. Black H. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun. 2003;17:350–364.
    1. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovary syndrome to healthy controls. Psychosom Med. 2004;66:356–362.
    1. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554–1565.
    1. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci. 1999;96:513–523.
    1. Timonen M, Laakso M, Jokelainen J, Rajala U, Meyer-Rochow VB, Keinänen-Kiukaanniemi S. Insulin resistance and depression: cross sectional study. BMJ. 2005;330:17–18.
    1. Pan A, Ye X, Franco OH, Li H, Yu Z, Zou S, et al. Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord. 2008;109:75–82.
    1. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–477.
    1. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007;13:527–537.
    1. Nestler JE. Metformin for the treatment of polycystic ovary syndrome. N Engl J Med. 2008;358:47–54.
    1. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002;13:251–257.
    1. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med. 2008;9:987–992.
    1. Polycystic ovary syndrome. [Accessed February 20, 2009]. (n.d.) Available at: .
    1. Polycystic ovary syndrome. [Accessed February 20, 2009]. (n.d.) Available at: .
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
    1. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovary syndrome. Reprod Biomed Online. 2006;12:569–578.
    1. Despres JP, Lemieux I, Prud`homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716–720.
    1. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:812–819.
    1. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470–1474.
    1. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A, et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod. 2008;23:642–650.
    1. Brown AJ, Setji TL, Sanders LL, Lowry KP, Otvos JD, Kraus WE, et al. Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. Med Sci Sports Exerc. 2009;41:497–504.
    1. Ryder JW, Chibalin AV, Zierath JR. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol Scand. 2001;171:249–257.
    1. Manneras L, Jonsdottir IH, Holmang A, Lonn M, Stener-Victorin E. Low-frequency electro-acupuncture and physical exercise improve metabolic disturbances and modulate gene expression in adipose tissue in rats with dihydrotestosterone-induced polycystic ovary syndrome. Endocrinology. 2008;149:3559–3568.
    1. Church TS, Barlow CD, Earnest CP, Kampert JB, Priest EL, Blaire SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 2002;22:1869–1876.
    1. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein W, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol. 2005;100:93–99.
    1. Giallauria F, Palomba S, Maresca L, Vuolo L, Tafuri D, Lombardi G, et al. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS) Clin Endocrinol. 2008;69:792–798.
    1. Liao LM, Nesic J, Chadwick PM, Brooke-Wavell K, Prelevic GM. Exercise and body image distress in overweight and obese women with polycystic ovary syndrome: A pilot investigation. Gynecol Endocrinol. 2008;24:555–561.
    1. Manlove HA, Guillermo C, Gray PB. Do women with polycystic ovary syndrome (PCOS) report differences in sex-typed behavior as children and adolescents? Results of a pilot study. Ann Human Biol. 2008;35:584–595.
    1. Galletly C, Moran L, Noakes M, Clifton P, Tomlinson L, Norman R. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome—A pilot study. Appetite. 2007;49:590–593.
    1. Markus CR, Olivier B, Panhuysen GE, Van der Gugten J, Alles MS, Tuiten A, et al. The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids and in vulnerable subjects raises brain serotonin activity reduces cortisol concentration and improves mood under stress. Am J Clin Nutr. 2000;71:1536–1544.
    1. Gonzalez F, Rote N, Minium J, Kirwan J. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-α release in obese women with polycystic ovary syndrome. J Endocrinol. 2006;188:521–529.
    1. Gonzalez F, Rote N, Minium J, Kirwan J. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336–34.
    1. Bonnet F, Irving K, Terra JL, Nony P, Berthezene F, Moulin P. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis. 2005;178:339–344.
    1. Lysy Z, Da cost A, Dasgupta K. The association of physical activity and depression in Type 2 diabetes. Diabet Med. 2008;25:1133–1141.
    1. Brosse AL, Sheets ES, Lett HS, Blumenthal JA. Exercise and the treatment of clinical depression in adults: recent findings and future directions. Sports Med. 2002;32:741–760.
    1. Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000;62:633–638.
    1. Antoni MH, Cruess S, Cruess D, Kumar M, Lutgendorf S, Ironson G, et al. Cognitive behavioral stress management reduces distress and 24-hour urinary free cortisol among symptomatic HIV-infected gay men. Ann Behav Med. 2000;22:29–37.
    1. Cruess DG, Antoni MH, McGregor BA, Kilbourn KM, Boyers AE, Alferi SM, et al. Cognitive-behavioral stress management reduces serum cortisol by enhancing positive contributions among women being treated for early stage breast cancer. Psychosom Med. 2000;62:304–308.
    1. Phillips K, Antoni MH, Lechner S, Blomberg BB, Llabre MM, Avisar E, et al. Stress Management Intervention Reduces Serum Cortisol and Increases Relaxation During Treatment for Non-Metastatic Breast Cancer. Psychosom Med. 2008;70:1044–1049.
    1. Antoni MH, Cruess D, Cruess S, Lutgendorf S, Kumar M, Ironson G, et al. Cognitive behavioral stress management effects on anxiety, 24-hour urinary catecholamine output, and T-Cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men. J Consult Clin Psychol. 2000;68:31–45.
    1. Cruess D, Antoni MH, Mahendra K, McGregor B, Alferi S, Boyers A, et al. Effects of stress management on testosterone levels in women with early-stage breast cancer. Int J Behav Med. 2001;8:194–207.
    1. Rofey DL, Szigethy EM, Noll RB, Dahl RE, Lobst E, Arslanian SA. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: A pilot study. J Pediatr Psychol. 2009;34:156–163.
    1. Mefferd K, Nichols J, Pakiz B, Rock CL. A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors. Breast Cancer Res Treat. 2007;104:145–152.
    1. Vignolo M, Rossi F, Bardazza G, Pistorio A, Parodi A, Spigno S, et al. Five-year follow-up of a cognitive-behavioural lifestyle multidisciplinary programme for childhood obesity outpatient treatment. Eur J Clin Nutr. 2008;62:1047–1057.
    1. Ash S, Reeves M, Bauer J, Dover T, Vivanti A, Leong C, et al. A randomized control trial comparing lifestyle groups, individual counseling and written information in the management of weight and health outcomes over 12 months. Int J Obes. 2006;30:1557–1564.
    1. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress, and sexuality. Hum Reprod. 2006;21:1925–1934.
    1. Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry. 1997;171:328–334.
    1. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry. 1998;55:816–820.
    1. Gould RA, Ott MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev. 1995;15:819–844.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner